Although there have been no clinical trials there is an enormous number of case studies showing the benefit of low dose naltrexone for cancer treatment, especially in latter stages of cancer
It appears that low dose naltrexone can block tumor formation and cell proliferation.
- Naltrexone at low doses (LDN) and its relevance to cancer therapy – Wai M Liu, Angus G Dalgleish
- Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy – Wai M. Liu Katherine A. Scott Jayne L. Dennis Elwira Kaminska Alan J. Levett Angus G. Dalgleish
- Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy – Zijian Li, Yue You, Noreen Griffin, Juan Feng, Fengping Shan
- Low Doses Naltrexone: The Potential Benefit Effects for its Use in Patients with Cancer – Ricardo David Couto, Bruno Jose Dumêt Fernandes
- Preclinical and clinical studies into the bioactivity of low-dose naltrexone (LDN) for oncotherapy – Na Qua, Yiming Meng, Mike K. Handley, Chunyan Wang, Fengping Shan
- Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway – Ning Liua, Limei Yana, Fengping Shan, Xiaonai Wang, Na Qu, Mike K Handley, Mingxing Ma